BIOMARKER:

BCL2 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	pixantrone Sensitive: C3 – Early Trials pixantrone Sensitive : C3	pixantrone Sensitive: C3 – Early Trials pixantrone Sensitive : C3
BCL2 positive	Estrogen Receptor Positive Breast Cancer	BCL2 positive	Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + ibrutinib Sensitive: D – Preclinical venetoclax + ibrutinib Sensitive : D	venetoclax + ibrutinib Sensitive: D – Preclinical venetoclax + ibrutinib Sensitive : D
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D